Main Menu
Main Menu
Ravi Kumar Monangi / / 3 minutes of reading

Building DSCSA Readiness and Supply Chain Scalability for Commercial Launch

What is DSCSA and Why It Matters

The Drug Supply Chain Security Act (DSCSA) is a U.S. federal law that establishes a national system to track and trace prescription drugs as they move through the supply chain. It requires every package to carry a unique identifier and mandates interoperable electronic data exchange. This protects patients by preventing counterfeit, diverted, or contaminated products from reaching the market. 

By the regulatory deadline November 27th 2024, all manufacturers, wholesalers, and dispensers must have electronic systems in place to exchange serialization data, verify product authenticity, and maintain full supply chain visibility. For emerging and late‑stage companies preparing for their first commercial launch, DSCSA is not just a compliance requirement—it is a critical milestone. Without DSCSA‑compliant processes and systems, products cannot legally be distributed in the U.S. market. Establishing these capabilities early creates a transparent, scalable, and resilient supply chain. 

Why Companies in Late‑Stage Clinical Must Act Now

Organizations nearing commercialization are transitioning from research and development to market‑facing operations. Achieving DSCSA compliance and connecting supply chain partners such as contract manufacturers, 3PLs, and distributors before launch is essential to avoid costly delays, shipment holds, or compliance risks.

Immediate Actionable Steps

  • Assess your supply network: Map out CMOs, packaging sites, and 3PLs; verify their serialization and data‑sharing readiness. 
  • Select a digital supply chain platform: Evaluate solutions such as TraceLink MINT, SAP ATTP, or Systech to enable interoperable serialization and visibility. 
  • Integrate with your ERP: Connect the chosen platform with ERP systems like Oracle NetSuite to unify operational and financial data.
  • Establish governance and SOPs: Create and train teams on workflows for EPCIS data management, product verification, and investigation processes. 
  • Run pilot tests: Conduct end‑to‑end validation with at least one product and supply partner well ahead of launch. 

Phased Roadmap to Commercial Readiness (T‑minus Approach)

 

Phase 

T‑Minus Milestone 

Key Activities 

Outcome 

Foundation 

T‑12 to T‑9 months before launch 

  • Deploy serialization and visibility platform  
  • Begin ERP integration 
  • Start onboarding CMOs and 3PLs 

Compliance infrastructure and data flows established 

Optimization 

T‑9 to T‑6 months before launch 

  • Test EPCIS data exchanges end‑to‑end
  • Build dashboards and analytics
  • Train staff on SOPs 

Operational readiness and data confidence 

Scale & Launch 

T‑6 months to launch and beyond 

  • Add additional products and partners
  • Use analytics for planning and inventory control
  • Refine workflows post‑launch 

Scalable, launch‑ready supply chain 

How Celito Can Help

  • Celito partners with life sciences organizations to guide them through this process. 

    • Implementation expertise: We configure and deploy supply chain platforms and integrate them with ERP systems like NetSuite. 
    • Computer system validation (CSV): We deliver validation plans, test scripts, and regulatory documentation aligned with FDA and GxP standards. 
    • Ongoing system administration: We manage serialization data flows, onboard new partners, and ensure systems run smoothly as companies scale. 

Conclusion

DSCSA compliance is more than a regulatory hurdle; it is a catalyst for building a future‑proof supply chain. By following a phased roadmap and leveraging the right platforms integrated with ERP, companies can confidently transition from clinical development to a successful commercial launch.